TOPICAL DELIVERY OF ANTI-INFLAMMATORY COMPOUNDS 353 (20) M. Siewert, J. Dressman, C. K. Brown, and V. P. Shah, FIP/AAPS guidelines to dissolution/in vitro re- lease testing of novel/special dosage forms, AAPS Pharm. Sci. Tech., 4, E7 (2003). (21) E. Esposito, R. Cortesi, M. Drechsler, L. Paccamiccio, P. Mariani, C. Contado, E. Stellin, E. Menegatti, F. Bonina, and C. Puglia, Cubosome dispersions as delivery systems for percutaneous administration of indomethacin, Pharm. Res., 22, 2163–2173 (2005). (22) J.B. Dawson, D. J. Barker, D. J. Ellis, E. Grassam, J. A. Cotterill, G. W. Fisher, and J. W. Feather, A theoretical and experimental study of light absorption and scattering by in vivo skin, Phys. Med. Biol., 25, 695–709 (1980). (23) R. J. Scheuplein and I. H. Blank, Mechanism of percutaneous absorption. IV. Penetration of nonelectro- lytes (alcohols) from aqueous solution and from pure liquid, J. Invest. Dermatol., 60, 286–296 (1973).
Previous Page Next Page